Table of contents
May 2005 Vol 5 No 5
In this issue
p331 | doi:10.1038/nrc1626
Research Highlights
Therapeutics: A positive defect
p333 | doi:10.1038/nrc1618
Tumour suppressors: Mob-handed?
p334 | doi:10.1038/nrc1617
In the news
HPV jab success
p334 | doi:10.1038/nrc1622
Therapeutics: Holistic design
p335 | doi:10.1038/nrc1620
In brief
Tumorigenesis | Epigenetics | Therapeutics | Cancer suppression
p335 | doi:10.1038/nrc1621
Tumorigenesis: The collagen connection
p336 | doi:10.1038/nrc1615
Oncogenes: Trousseau's sign
p336 | doi:10.1038/nrc1624
Tumorigenesis: Micromanager
p337 | doi:10.1038/nrc1614
Cancer genetics: A killing combination
p338 | doi:10.1038/nrc1616
Tumorigenesis: Route master
p338 | doi:10.1038/nrc1623
Epidemiology: Minority report
p339 | doi:10.1038/nrc1619
Trial Watch
Double whammy | Jury still out on erythropoietin
p339 | doi:10.1038/nrc1625
Reviews
ERBB receptors and cancer: the complexity of targeted inhibitors
Nancy E. Hynes & Heidi A. Lane
p341 | doi:10.1038/nrc1609
Ovarian Cancer Metastasis: Integrating insights from disparate model organisms
Honami Naora & Denise J. Montell
p355 | doi:10.1038/nrc1611
Molecular genetics of multiple endocrine neoplasia types 1 and 2
Stephen J. Marx
p367 | doi:10.1038/nrc1610
The runx genes: gain or loss of function in cancer
Karen Blyth, Ewan R. Cameron & James C. Neil
p376 | doi:10.1038/nrc1607
The Nurses' Health Study: lifestyle and health among women
Graham A. Colditz & Susan E. Hankinson
p388 | doi:10.1038/nrc1608
Perspectives
Opinion
Immunotherapy and chemotherapy — a practical partnership
Richard A. Lake & Bruce W.S. Robinson
p397 | doi:10.1038/nrc1613
Opinion
Post-prenylation-processing enzymes as new targets in oncogenesis
Ann M. Winter-Vann & Patrick J. Casey
p405 | doi:10.1038/nrc1612
